Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | KYTX | Stock Option (Right to Buy) | Feb 7, 2024 | Common Stock | 33K | $4.83 | Direct | F1 | ||||||
holding | KYTX | Series A-1 Redeemable Convertible Preferred Stock | Feb 7, 2024 | Common Stock | 967K | See footnote | F2, F3 | |||||||
holding | KYTX | Series A-2 Redeemable Convertible Preferred Stock | Feb 7, 2024 | Common Stock | 1.94M | See footnote | F2, F3 | |||||||
holding | KYTX | Series B Redeemable Convertible Preferred Stock | Feb 7, 2024 | Common Stock | 880K | See footnote | F2, F3 | |||||||
holding | KYTX | Series B Redeemable Convertible Preferred Stock | Feb 7, 2024 | Common Stock | 736K | See footnote | F2, F4 |
Id | Content |
---|---|
F1 | 25% of the original number of shares subject to the option shall vest on January 1, 2025, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. |
F2 | The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock has no expiration date and is convertible into the Issuer's Common Stock on a 1-for-4.5511 basis at any time. The number of underlying shares of Common Stock reported in Column 3 reflects an automatic conversion of each outstanding share of Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock into shares of Common Stock at a ratio of 1-for-4.5511 to be effective immediately prior to the closing of the Issuer's initial public offering. |
F3 | Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, the Reporting Person and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any. |
F4 | Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The voting and dispositive control over Westlake Opportunity GP I is shared by the managing directors of Westlake Opportunity GP I, the Reporting Person and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any. |
Exhibit 24 - Power of Attorney